Ausgabe 1/2008
Inhalt (20 Artikel)
Whither Autoimmunity: The Lessons of Anti-CCP and B cell Depletion
Yehuda Shoenfeld, M. Eric Gershwin
Antibodies to Citrullinated Vimentin are a Specific and Sensitive Marker for the Diagnosis of Rheumatoid Arthritis
Hannah Poulsom, Peter J. Charles
Does the Presence of Anti-CCP Autoantibodies and Their Serum Levels Influence the Severity and Activity in Rheumatoid Arthritis Patients?
Nikolaos G. Papadopoulos, Georgios Z. Tsiaousis, Aikaterini Pavlitou-Tsiontsi, Anastasia Giannakou, Vassiliki K. Galanopoulou
Diagnostic Accuracy of Immunoassays for the Detection of Antibodies to Citrullinated Proteins
Nicola Bizzaro, Marilina Tampoia
Comparison of Three Anti-CCP Antibody Tests and Rheumatoid Factor in RA and Control Patients
Ma Lurdes Correia, Saudade Carvalho, Jorge Fortuna, Ma Henriqueta Pereira
Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis: As Good as it Gets?
Zoltán Szekanecz, Lilla Soós, Zoltán Szabó, Andrea Fekete, Anikó Kapitány, Anikó Végvári, Sándor Sipka, Gabriella Szücs, Sándor Szántó, Gabriella Lakos
Share Epitope, Citrullinated Cyclic Peptide Antibodies and Smoking in Brazilian Rheumatoid Arthritis Patients
Rene Donizeti Oliveira, Cristina Maria Junta, Fabíola Reis Oliveira, Lucienir Maria Silva, Eduardo Antonio Donadi, Paulo Louzada-Junior
Anti-CCP2 Antibodies: An Overview and Perspective of the Diagnostic Abilities of this Serological Marker for Early Rheumatoid Arthritis
Walther J. van Venrooij, Albert J. W. Zendman
Prevalence of Autoantibodies to Cyclic Citrullinated Peptide in Patients with Rheumatic Diseases other than Rheumatoid Arthritis: A French Multicenter Study
Nicole Fabien, Nils-Olivier Olsson, Joëlle Goetz, Catherine Johanet, Andrée Escande, Nathalie Bardin, Marielle Sanmarco, Chantal Andre, Alain Chevailler, René-Louis Humbel, Pascale Chretien, Jean-claude Monier, Françoise Fortenfant, Françoise Oksman, Marie-France Taillefer, Jean Sibilia
The Role of Anti-Cyclic Cytrullinate Antibodies Testing in Rheumatoid Arthritis
Cristiano Alessandri, Roberta Priori, Mariagrazia Modesti, Riccardo Mancini, Guido Valesini
B-Cell Depletion and Repopulation in Autoimmune Diseases
Jacques-Olivier Pers, Capucine Daridon, Boutahar Bendaoud, Valérie Devauchelle, Christian Berthou, Alain Saraux, Pierre Youinou
Rituximab in Treatment-Resistant Autoimmune Blistering Skin Disorders
Enno Schmidt, Eva-Bettina Bröcker, Matthias Goebeler
Analysis of Wegener’s Granulomatosis Responses to Rituximab: Current Evidence and Therapeutic Prospects
Achille Aouba, Christian Pagnoux, Boris Bienvenu, Alfred Mahr, Loïc Guillevin
Combined Therapy with Rituximab Plus Cyclophosphamide/Vincristine/Prednisone for Sjogren’s Syndrome-Associated B-Cell Non-Hodgkin’s Lymphoma
J. Carbone, R. Perez-Fernandez, A. Muñoz, P. Sabin, L. Carreño, E. Fernandez-Cruz
Rituximab as a Therapeutic Tool in Severe Mixed Cryoglobulinemia
Dario Roccatello, Simone Baldovino, Daniela Rossi, Osvaldo Giachino, Morteza Mansouri, Carla Naretto, Debora Di Simone, Simona Francica, Roberto Cavallo, Mirella Alpa, Franca Napoli, Luigi M. Sena
Rituximab Induces Distinct Intraorbital and Intrathyroidal Effects in One Patient Satisfactorily Treated for Graves’ Ophthalmopathy
P. Bonara, G. Vannucchi, I. Campi, S. Rossi, F. Cantoni, C. Frugoni, F. Sbrozzi, C. Guastella, S. Avignone, P. Beck-Peccoz, M. Salvi
Should Rituximab be Considered as the First-Choice Treatment for Severe Autoimmune Rheumatic Diseases?
Claudio Galarza, Diana Valencia, Gabriel J. Tobón, Luis Zurita, Rubén D. Mantilla, Ricardo Pineda-Tamayo, Adriana Rojas-Villarraga, Juan C. Rueda, Juan-Manuel Anaya